Status:
COMPLETED
MRI and Biomarkers in Prostate Cancer
Lead Sponsor:
Turku University Hospital
Conditions:
Prostate Cancer
Eligibility:
MALE
18-85 years
Phase:
NA
Brief Summary
Prostate cancer has been the most common neoplastic disease in men in Finland over the last ten years. Prostate-specific antigen (PSA) plays an important role in screening of prostate cancer. However,...
Eligibility Criteria
Inclusion
- Age: 18 to 85 years
- Clinical suspicion of prostate cancer, based on: serum level of PSA from 2,5 ng/ml to 20 ng/ml in two following measurements and/or abnormal digital rectal examination
- Mental status: Patients must be able to understand the meaning of the study
- Informed consent: The patient must sign the appropriate Ethics Committee (EC) approved informed consent documents in the presence of the designated staff
Exclusion
- previous prostate biopsies within 6 months
- previous diagnosis of prostate carcinoma
- previous prostate surgeries, e.g. TURP (transurethral prostatic resection)
- symptomatic of acute prostatitis
- contraindications for MRI (cardiac pacemaker, intracranial clips etc)
- uncontrolled serious infection
- claustrophobia
- hip replacement surgery or other metal implants in the pelvic area
Key Trial Info
Start Date :
April 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2018
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT02241122
Start Date
April 1 2015
End Date
April 1 2018
Last Update
April 18 2018
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Urology, Helsinki University Hospital
Helsinki, Finland
2
Department of Urology, Kuopio University Hospital
Kuopio, Finland
3
Department of Urology, Pori Central Hospital
Pori, Finland
4
Department of Urology, Tampere University Hospital
Tampere, Finland